Table 1 Patient and treatment characteristics
Characteristic | No. of patients (%) (N = 34) |
|---|---|
Age (mean) | 60Â years |
Smoking history (median) | 35 pack-years |
Gender | Â |
 Male | 27 (79%) |
 Female | 7 (21%) |
AJCC 7th edition Stage | Â |
 III | 3 (9%) |
 IVa | 28 (82%) |
 IVb | 3 (9%) |
AJCC 8th edition stage | Â |
 II (P16 positive) | 17 (50%) |
 III (P16 positive) | 4 (12%) |
 III (p16 negative) | 3 (9%) |
 IVa (p16 negative) | 10 (29%) |
T Classification | Â |
 T1 | 2 (6%) |
 T2 | 15 (44%) |
 T3 | 11 (32%) |
 T4a | 5 (15%) |
 T4b | 1 (3%) |
N Classification | Â |
 N0 | 1 (3%) |
 N1 | 5 (15%) |
 N2a | 5 (15%) |
 N2b | 14 (41%) |
 N2c | 9 (26%) |
Primary site | Â |
 Tonsil | 19 (56%) |
 Base of tongue | 13 (38%) |
 Pharyngeal wall | 1 (3%) |
 Soft palate | 1 (3%) |
Mean boost volume | 54 cc (range 13–185 cc) |
 8 Gy SRS boost | 11 (32%) |
 10 Gy SRS boost | 16 (47%) |
 5 Gy × 2 SRS boost | 7 (21%) |
HPV status | Â |
 HPV-positive smokers | 21 (62%) |
 HPV-negative | 13 (38%) |
Chemotherapy | Â |
 Cisplatin | 27 (79%) |
 Cetuximab | 1 (3%) |
 Carboplatin paclitaxel | 1 (3%) |
 Cisplatin followed by carboplatin and paclitaxel | 4 (12%) |
 Unknown | 1 (3%) |